UBS analyst Matthew Weston upgraded Novartis to Buy from Neutral with a price target of CHF 104, up from CHF 90, after assuming coverage of the name. The company is well-owned but its high R&D productivity provides strong foundation for growth, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVS:
- Cytokinetics extends decline, down 26% after WSJ said Novartis back away
- Novartis backing away from pursuit of Cytokinetics, WSJ reports
- Cytokinetics sinks 23% after WSJ says Novartis backed away from takeover
- M & A News: CYTK Stock Drops, Novartis Deal Hopes Diminish
- Cytokinetics slips after Novartis CEO says M&A focus on ‘bolt ons’
